Go Pro
→ How Elon’s Empire Ends (and how to profit) (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$260.64
+0.3%		$257.79
$190.75
▼
$269.39
$460.48B0.246.41 million shs2,208 shs
Amgen Inc. stock logo
AMGN
Amgen
$405.69
-0.4%		$410.18
$288.00
▼
$447.03
$219.33B0.412.75 million shs5,103 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$146.65
-0.6%		$143.32
$109.66
▼
$157.29
$182.08B0.316.85 million shs72,014 shs
Moderna, Inc. stock logo
MRNA
Moderna
$189.76
+0.4%		$122.75
$22.28
▼
$208.90
$75.85B1.0913.94 million shs15.41 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.94%-1.92%+0.03%-0.36%+6.20%
Amgen Inc. stock logo
AMGN
Amgen
-3.38%+0.30%-7.04%+8.85%+36.44%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.04%-1.46%-1.61%+12.36%+32.70%
Moderna, Inc. stock logo
MRNA
Moderna
-1.89%-3.02%+22.47%+136.89%+584.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$260.64
+0.3%		$257.79
$190.75
▼
$269.39
$460.48B0.246.41 million shs2,208 shs
Amgen Inc. stock logo
AMGN
Amgen
$405.69
-0.4%		$410.18
$288.00
▼
$447.03
$219.33B0.412.75 million shs5,103 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$146.65
-0.6%		$143.32
$109.66
▼
$157.29
$182.08B0.316.85 million shs72,014 shs
Moderna, Inc. stock logo
MRNA
Moderna
$189.76
+0.4%		$122.75
$22.28
▼
$208.90
$75.85B1.0913.94 million shs15.41 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.94%-1.92%+0.03%-0.36%+6.20%
Amgen Inc. stock logo
AMGN
Amgen
-3.38%+0.30%-7.04%+8.85%+36.44%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-1.04%-1.46%-1.61%+12.36%+32.70%
Moderna, Inc. stock logo
MRNA
Moderna
-1.89%-3.02%+22.47%+136.89%+584.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.87
Moderate Buy$272.664.89% Upside
Amgen Inc. stock logo
AMGN
Amgen
2.33
Hold$385.25-5.41% Downside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.79
Moderate Buy$158.787.65% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$77.83-58.81% Downside

Current Analyst Ratings Breakdown

Latest ABBV, AMGN, GILD, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$60.00 ➝ $80.00
9/29/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/28/2026
Amgen Inc. stock logo
AMGN
Amgen
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$450.00 ➝ $500.00
9/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/23/2026
Amgen Inc. stock logo
AMGN
Amgen
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$410.00
9/23/2026
Amgen Inc. stock logo
AMGN
Amgen
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
Singular Research logo
Singular Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
9/22/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/17/2026
Amgen Inc. stock logo
AMGN
Amgen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$430.00
9/16/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$250.00 ➝ $240.00
9/14/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.51$15.05 per share17.27($1.83) per share-142.05
Amgen Inc. stock logo
AMGN
Amgen
$36.75B5.99$32.66 per share12.47$16.08 per share25.33
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B6.21$10.36 per share14.24$18.23 per share8.09
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B38.80N/AN/A$22.14 per share8.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5473.4316.131.199.80%-422.07%14.34%10/30/2026 (Estimated)
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0925.3116.653.0422.95%124.14%13.18%11/3/2026 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$2.67N/A14.94N/A-10.64%-2.11%-0.75%10/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)

Latest ABBV, AMGN, GILD, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.86N/AN/AN/A$17.31 billionN/A
10/29/2026Q3 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.12N/AN/AN/A$7.77 billionN/A
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
8/3/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.25-$6.75+$0.50-$8.45$7.40 billion$7.80 billion
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.66%+6.80%195.48%53 Years
Amgen Inc. stock logo
AMGN
Amgen
$10.082.48%+8.27%62.65%14 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.22%+3.04%N/A 10 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ABBV, AMGN, GILD, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.71%10/15/202610/15/202611/16/2026
7/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.24%9/15/20269/15/20269/29/2026
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.29%8/21/20268/21/20269/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.03
1.27
1.09
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
 |  stocktwits.comS
Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078286
Moderna stock rises 2% on Nasdaq 100 entry but this analyst says sell
 |  invezz.comI
Moderna loses US government license defense in Northwestern patent case
October 2 at 1:27 AM  |  reuters.comhttps://www.reuters.com/legal/government/moderna-loses-us-government-license-defense-northwestern-patent-case-2026-10-01/
Moderna slips as Citi cuts to Sell on “unjustifiable” valuation
October 2 at 1:27 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4648418-moderna-stock-slips-citi-cuts-sell
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
October 1 at 8:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/moderna-mrna-stock-dips-while-205005439.html
Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
October 1 at 8:27 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/moderna-inc-join-nasdaq-100-000000029.html
Moderna to replace Warner Bros Discovery  on Nasdaq 100
October 1 at 8:12 PM  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/moderna-join-nasdaq-100-replacing-warner-bros-discovery-2026-10-02/
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
October 1 at 6:50 PM  |  zacks.comhttps://www.zacks.com/stock/news/2999206/moderna-mrna-stock-dips-while-market-gains-key-facts?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2999206
After Moderna's 'Outsized Run,' It May Be Time For This Bearish Move
October 1 at 3:26 PM  |  msn.comhttps://www.msn.com/en-us/news/other/after-modernas-outsized-run-it-may-be-time-for-this-bearish-move/ar-AA2dmyvv
Top Healthcare Stocks To Watch Today - October 1st
October 1 at 1:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-top-healthcare-stocks-to-watch-today-october-1st-2026-10-01/
Biotech Stocks To Watch Now - October 1st
October 1 at 12:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-biotech-stocks-to-watch-now-october-1st-2026-10-01/
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
October 1 at 11:00 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/01/moderna-climbs-3-despite-citigroups-downgrade-to-sell-biontech-inches-higher-pfizer-treads-water/?utm_source=snapi
Citi delivers major verdict after Moderna’s remarkable 703% run
October 1 at 10:16 AM  |  thestreet.comhttps://www.thestreet.com/investing/stocks/mrna-mordena-stock-citi-downgrades-to-sell-raises-price-target-after-703-run
Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz
October 1 at 10:16 AM  |  finance.yahoo.comhttps://finance.yahoo.com/m/fdcf8835-313e-3fae-93cc-4997a4b9dc95/is-a-cancer-vaccine-coming%3F.html
Critical Contrast: Moderna (NASDAQ:MRNA) & BioStem Technologies (OTCMKTS:BSEM)
October 1 at 6:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073795
This Analyst Just Downgraded Moderna Stock. Here's Why.
September 30 at 11:45 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/analyst-just-downgraded-moderna-stock-204057714.html
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
September 30 at 4:06 PM  |  investopedia.comhttps://www.investopedia.com/market-update-moderna-stock-slumps-as-citi-says-its-time-to-sell-after-500-rally-this-year-mrna-12149780
Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal
September 30 at 3:28 PM  |  benzinga.comhttps://www.benzinga.com/opinion/26/09/62091512/moderna-shares-reverse-weakness-rise-3-percent-after-key-trading-signal?utm_source=snapi
Moderna Names Juan Andres as COO
September 30 at 1:43 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/moderna-names-juan-andres-coo-113715436.html
Moderna Shares Slump As Citi Downgrades To 'Sell’ After Cancer Vaccine Rally
September 30 at 1:43 PM  |  forbes.comhttps://www.forbes.com/sites/maryroeloffs/2026/09/30/moderna-shares-slump-as-citi-downgrades-to-sell-after-cancer-vaccine-rally/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Amgen logo displayed on a glass panel in a laboratory setting with microscopes and sample vials.
Amgen Drops 10% on a Trial It Didn't Even Run
By Chris Markoch | September 11, 2026
Laboratory workbench with chromatography instrument, pipettes, sample vials, and a notebook, with a production line visible beyond the glass wall.
3 Healthcare Dividend Stocks Offering More Than Just Income
By Chris Markoch | September 30, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$260.31 +0.38 (+0.15%)
As of 09:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Amgen stock logo

Amgen NASDAQ:AMGN

$405.21 -2.06 (-0.51%)
As of 09:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$146.72 -0.78 (-0.53%)
As of 09:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$189.63 +0.69 (+0.36%)
As of 09:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas